We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Biomarker Linked to Inflammation in Vascular Disease

By LabMedica International staff writers
Posted on 05 Aug 2010
A blood component linked with inflammation can predict coronary artery disease in Americans of African descent.

The blood factor, lipoprotein-associated phospholipase A2 (Lp-PLA2), is also associated with, but does not accurately predict, heart-disease risk in Caucasians. More...
Scientists measured Lp-PLA2 levels in the blood of 336 Caucasians and 224 Americans of African descent who were about to be tested to determine coronary artery disease in high-risk patients. Coronary arteriography findings were compared with the amount and activity levels of Lp-PLA2 from each patient.

During the procedure, contrast dye and X-rays were used to detect narrowed or blocked arteries, indicating the potential for heart attacks. The outcomes showed that Lp-PLA2 activity was higher among Caucasians and Americans of African descent with coronary artery disease. In addition, only in the latter was the Lp-PLA2 index found to predict independently coronary artery disease.

"This study suggests that inflammation may be a more important mechanism in heart disease for African-Americans than it is for Caucasians and increases our growing understanding of how heart-disease processes vary in different ethnic groups," said Lars Berglund, senior study author and associate dean for research at the UC Davis School of Medicine. "The more we appreciate such differences, the better we can individualize treatment and prevention approaches."

Lp-PLA2 was recently identified as a marker for the inflammatory processes involved in atherosclerosis. It is considered key to the progression and rupture of fatty plaques that can block coronary arteries and lead to heart attacks.

The scientific team plans further studies of Lp-PLA2 and other inflammatory components of blood in a wider range of patients to get a clearer picture of their roles in predicting heart disease for different ethnic and racial groups.

The study was performed at the University of California (UC) Davis School of Medicine (Sacramento, CA, USA). Findings were published in the July 2010 issue of the Journal of Clinical Endocrinology and Metabolism.

Related Links:
UC Davis School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.